NYMC Faculty Publications
Allotransplantation for Patients Age ≥40 Years With Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival
Author Type(s)
Faculty
DOI
10.1016/j.bbmt.2014.03.013
Journal Title
Biology of Blood and Marrow Transplantation
First Page
960
Last Page
968
Document Type
Article
Publication Date
7-1-2014
Department
Pediatrics
Keywords
Adult, Age Factors, Disease-Free Survival, Female, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Survival Analysis, Transplantation Conditioning, Transplantation, Homologous
Disciplines
Medicine and Health Sciences
Abstract
Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow Transplant Research data on 1248 patients age ≥40 years receiving reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning HCT for aggressive (n = 668) or indolent (n = 580) NHL. Aggressive lymphoma was more frequent in the oldest cohort 49% for age 40 to 54 versus 57% for age 55 to 64 versus 67% for age ≥65; P = .0008). Fewer patients aged ≥65 had previous autografting (26% versus 24% versus 9%; P = .002). Rates of relapse, acute and chronic GVHD, and nonrelapse mortality (NRM) at 1 year post-HCT were similar in the 3 age cohorts (22% [95% confidence interval (CI), 19% to 26%] for age 40 to 54, 27% [95% CI, 23% to 31%] for age 55 to 64, and 34% [95% CI, 24% to 44%] for age ≥65. Progression-free survival (PFS) and overall survival (OS) at 3 years was slightly lower in the older cohorts (OS: 54% [95% CI, 50% to 58%] for age 40 to 54; 40% [95% CI, 36% to 44%] for age 55 to 64, and 39% [95% CI, 28% to 50%] for age ≥65; P < .0001). Multivariate analysis revealed no significant effect of age on the incidence of acute or chronic GVHD or relapse. Age ≥55 years, Karnofsky Performance Status
Recommended Citation
McClune, B. L., Cairo, M., & Weisdorf, D. J. (2014). Allotransplantation for Patients Age ≥40 Years With Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 20 (7), 960-968. https://doi.org/10.1016/j.bbmt.2014.03.013
Comments
Please see the work itself for the complete list of authors.